Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.80 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.80 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.80 |
| ▸ | LMNA | P02545 | 3/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.80 |
| ▸ | MAPT | P10636 | 3/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.80 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.80 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.80 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.80 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.80 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.80 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.80 |
| ▸ | SCN1A | P35498 | 2/20 | 0.80 |
| ▸ | HTR2B | P41595 | 2/20 | 0.80 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.80 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6727785 | 0.96 | CACNA1D (0.72) | ADORA3CYP1A2HIF1ACACNA1CLMNA | |
| SCHEMBL10909420 | 0.94 | ADORA3 (0.77) | ADORA3CYP1A2HIF1ACACNA1CLMNA | |
| SCHEMBL11824944 | 0.92 | CYP1A2 (0.82) | ADORA3CYP1A2HIF1ACACNA1CLMNA | |
| SCHEMBL5085498 | 0.92 | ADORA3 (0.86) | ADORA3CYP1A2HIF1ACACNA1CLMNA | |
| SCHEMBL7425673 | 0.92 | ADORA3 (0.68) | ADORA3CYP1A2HIF1ACACNA1CLMNA | |
| SCHEMBL10899662 | 0.92 | CACNA1C (0.74) | ADORA3CYP1A2HIF1ACACNA1CLMNA | |
| SCHEMBL10901029 | 0.92 | CACNA1C (0.74) | ADORA3CYP1A2HIF1ACACNA1CLMNA | |
| SCHEMBL6727797 | 0.91 | CACNA1B (0.70) | ADORA3CYP1A2HIF1ACACNA1CLMNA | |
| SCHEMBL9673129 | 0.91 | ADORA3 (0.80) | ADORA3CYP1A2HIF1ACACNA1CLMNA | |
| SCHEMBL9175041 | 0.91 | ADORA3 (0.80) | ADORA3CYP1A2HIF1ACACNA1CLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6545028-B2 | Antiepileptic agents, hypotensive agents; monitoring membrane potentials | NEUROSEARCH A/S (DK) | 2003-04-08 | — | — | US | claimed |
| US-20020119989-A1 | Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction | ANIONA APS (DK) | 2002-08-29 | — | — | US | claimed |
| US-6545028-B2 | Antiepileptic agents, hypotensive agents; monitoring membrane potentials | NEUROSEARCH A/S (DK) | 2003-04-08 | — | — | US | disclosed |
| US-20020119989-A1 | Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction | ANIONA APS (DK) | 2002-08-29 | — | — | US | disclosed |
| US-3932645-A | CORONARY VASODILATORS, HYPOTENSIVE AGENTS | FARBENFABRIKEN BAYER AG (DT) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119989-A1 | Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction | KCNN2, KCNN1, KCNJ2 | ADORA3 1409/4885CYP1A2 3170/4885HIF1A 2396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.